{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-129900","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2022-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.906139+00:00","generated_at":"2026-06-20T23:45:45.753170+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Theriva repurchases 720k shares from subsidiary founders at $0.4001/share for $288k","bullets":["Repurchased 720,000 shares from three founders (Manel Maria Cascallo Piqueras, Ramon Alemany, Gabriel Maria Capella Minar) at $0.4001 per share.","Aggregate purchase price of $288,072; funded from cash on hand; shares will be held as treasury stock.","Selling stockholders originally acquired shares as consideration for sale of subsidiary to Theriva in March 2022.","Transaction privately negotiated; not part of a broader buyback program."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-129900","json":"https://secwatch.observer/filing/0001104659-22-129900.json","markdown":"https://secwatch.observer/filing/0001104659-22-129900.md","text":"https://secwatch.observer/filing/0001104659-22-129900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465922129900/0001104659-22-129900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465922129900/tm2233416d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T23:45:45.753170+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"065a9e533c3fa7ae5d35a2b6bffd85517fbc932c","claim":"Theriva Biologics, Inc. entered into Share Repurchase Agreement with Manel Maria Cascallo Piqueras, Ramon Alemany and Gabriel Maria Capella Minar valued at $288,072 (effective 2022-12-20).","evidence_excerpt":"On December 22, 2022, Theriva Biologics, Inc. (the “Company”) repurchased an aggregate of 720,000 shares of its common stock, par value $0.0001 (the “Common Stock”) from Manel Maria Cascallo Piqueras, Ramon Alemany and Gabriel Maria Capella Minar (the “Selling Stockholders”), three founders of its subsidiary Theriva Biosciences S.L. (formerly known as VCN Biosciences S.L.) in a privately negotiated transaction pursuant to the terms of a Share Repurchase Agreement entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) entered into on December 20, 2022 with each of the Selling Stockholders. The price per share was $0.4001, which was the closing price of the Common Stock on the day prior to the closing for an aggregate purchase price was $288,072.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465922129900/0001104659-22-129900-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Manel Maria Cascallo Piqueras, Ramon Alemany and Gabriel Maria Capella Minar"},{"label":"Value","value":"$288,072"},{"label":"Effective","value":"2022-12-20"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}